Cargando…

Effectiveness of platelet-rich plasma in the treatment of Achilles tendon disease

BACKGROUND: The effectiveness of Platelet-Rich Plasma (PRP) in the treatment of patients with Achilles tendon rupture (ATR) and Achilles tendinopathy (AT) has been controversial. AIM: To assess PRP injections’ effectiveness in treating ATR and AT. METHODS: A comprehensive review of relevant literatu...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Dan, Vithran, Djandan Tadum Arthur, Gong, Hao-Li, Zeng, Ming, Tang, Zhong-Wen, Rao, Zhou-Zhou, Wen, Jie, Xiao, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292057/
https://www.ncbi.nlm.nih.gov/pubmed/37377997
http://dx.doi.org/10.5312/wjo.v14.i6.485
_version_ 1785062807921754112
author Huang, Dan
Vithran, Djandan Tadum Arthur
Gong, Hao-Li
Zeng, Ming
Tang, Zhong-Wen
Rao, Zhou-Zhou
Wen, Jie
Xiao, Sheng
author_facet Huang, Dan
Vithran, Djandan Tadum Arthur
Gong, Hao-Li
Zeng, Ming
Tang, Zhong-Wen
Rao, Zhou-Zhou
Wen, Jie
Xiao, Sheng
author_sort Huang, Dan
collection PubMed
description BACKGROUND: The effectiveness of Platelet-Rich Plasma (PRP) in the treatment of patients with Achilles tendon rupture (ATR) and Achilles tendinopathy (AT) has been controversial. AIM: To assess PRP injections’ effectiveness in treating ATR and AT. METHODS: A comprehensive review of relevant literature was conducted utilizing multiple databases such as Cochrane Library, PubMed, Web of Science, Chinese Science and Technology Journal, EMBASE, and China Biomedical CD-ROM. The present investigation integrated randomized controlled trials that assessed the effectiveness of platelet-rich plasma injections in managing individuals with Achilles tendon rupture and tendinopathy. The eligibility criteria for the trials encompassed publications that were published within the timeframe of January 1, 1966 to December 2022. The statistical analysis was performed utilizing the Review Manager 5.4.1, the visual analogue scale (VAS), Victorian Institute Ankle Function Scale (VISA-A), and Achilles Tendon Thickness were used to assess outcomes. RESULTS: This meta-analysis included 13 randomized controlled trials, 8 of which were randomized controlled trials of PRP for AT and 5 of which were randomized controlled trials of PRP for ATR. PRP for AT at 6 wk [weighted mean difference (WMD) = 1.92, 95%CI: -0.54 to 4.38, I(2) = 34%], at 3 mo [WMD = 0.20, 95%CI: -2.65 to 3.05, I(2) = 60%], and 6 mo [WMD = 2.75, 95%CI: -2.76 to 8.26, I(2) = 87%) after which there was no significant difference in VISA-A scores between the PRP and control groups. There was no significant difference in VAS scores between the PRP group and the control group after 6 wk [WMD = 6.75, 95%CI: -6.12 to 19.62, I(2) = 69%] and 6 mo [WMD = 10.46, 95%CI: -2.44 to 23.37, I(2) = 69%] of treatment, and at mid-treatment at 3 mo [WMD = 11.30, 95%CI: 7.33 to 15.27, I(2) = 0%] after mid-treatment, the PRP group demonstrated better outcomes than the control group. Post-treatment patient satisfaction [WMD = 1.07, 95%CI: 0.84 to 1.35, I(2) = 0%], Achilles tendon thickness [WMD = 0.34, 95%CI: -0.04 to 0.71, I(2) = 61%] and return to sport [WMD = 1.11, 95%CI: 0.87 to 1.42, I(2) = 0%] were not significantly different between the PRP and control groups. The study did not find any statistically significant distinction between the groups that received PRP treatment and those that did not, regarding the Victorian Institute of Sport Assessment - Achilles scores at 3 mo [WMD = -1.49, 95%CI: -5.24 to 2.25, I(2) = 0%], 6 mo [WMD = -0.24, 95%CI: -3.80 to 3.32, I(2) = 0%], and 12 mo [WMD = -2.02, 95%CI: -5.34 to 1.29, I(2) = 87%] for ATR patients. Additionally, no significant difference was observed between the PRP and the control groups in improving Heel lift height respectively at 6 mo [WMD = -3.96, 95%CI: -8.61 to 0.69, I(2) = 0%] and 12 mo [WMD = -1.66, 95%CI: -11.15 to 7.83, I(2) = 0%] for ATR patients. There was no significant difference in calf circumference between the PRP group and the control group after 6 mo [WMD = 1.01, 95%CI: -0.78 to 2.80, I(2) = 54%] and 12 mo [WMD = -0.55, 95%CI: -2.2 to 1.09, I(2) = 0%] of treatment. There was no significant difference in ankle mobility between the PRP and control groups at 6 mo of treatment [WMD = -0.38, 95%CI: -2.34 to 1.58, I(2) = 82%] and after 12 mo of treatment [WMD = -0.98, 95%CI: -1.41 to -0.56, I(2) = 10%] there was a significant improvement in ankle mobility between the PRP and control groups. There was no significant difference in the rate of return to exercise after treatment [WMD = 1.20, 95%CI: 0.77 to 1.87, I(2) = 0%] and the rate of adverse events [WMD = 0.85, 95%CI: 0.50 to 1.45, I(2) = 0%] between the PRP group and the control group. CONCLUSION: The use of PRP for AT improved the patient’s immediate VAS scores but not VISA-A scores, changes in Achilles tendon thickness, patient satisfaction, or return to sport. Treatment of ATR with PRP injections alone improved long-term ankle mobility but had no significant effect on VISA-A scores, single heel lift height, calf circumference or return to sport. Additional research employing more extensive sampling sizes, more strict experimental methods, and standard methodologies may be necessary to yield more dependable and precise findings.
format Online
Article
Text
id pubmed-10292057
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-102920572023-06-27 Effectiveness of platelet-rich plasma in the treatment of Achilles tendon disease Huang, Dan Vithran, Djandan Tadum Arthur Gong, Hao-Li Zeng, Ming Tang, Zhong-Wen Rao, Zhou-Zhou Wen, Jie Xiao, Sheng World J Orthop Meta-Analysis BACKGROUND: The effectiveness of Platelet-Rich Plasma (PRP) in the treatment of patients with Achilles tendon rupture (ATR) and Achilles tendinopathy (AT) has been controversial. AIM: To assess PRP injections’ effectiveness in treating ATR and AT. METHODS: A comprehensive review of relevant literature was conducted utilizing multiple databases such as Cochrane Library, PubMed, Web of Science, Chinese Science and Technology Journal, EMBASE, and China Biomedical CD-ROM. The present investigation integrated randomized controlled trials that assessed the effectiveness of platelet-rich plasma injections in managing individuals with Achilles tendon rupture and tendinopathy. The eligibility criteria for the trials encompassed publications that were published within the timeframe of January 1, 1966 to December 2022. The statistical analysis was performed utilizing the Review Manager 5.4.1, the visual analogue scale (VAS), Victorian Institute Ankle Function Scale (VISA-A), and Achilles Tendon Thickness were used to assess outcomes. RESULTS: This meta-analysis included 13 randomized controlled trials, 8 of which were randomized controlled trials of PRP for AT and 5 of which were randomized controlled trials of PRP for ATR. PRP for AT at 6 wk [weighted mean difference (WMD) = 1.92, 95%CI: -0.54 to 4.38, I(2) = 34%], at 3 mo [WMD = 0.20, 95%CI: -2.65 to 3.05, I(2) = 60%], and 6 mo [WMD = 2.75, 95%CI: -2.76 to 8.26, I(2) = 87%) after which there was no significant difference in VISA-A scores between the PRP and control groups. There was no significant difference in VAS scores between the PRP group and the control group after 6 wk [WMD = 6.75, 95%CI: -6.12 to 19.62, I(2) = 69%] and 6 mo [WMD = 10.46, 95%CI: -2.44 to 23.37, I(2) = 69%] of treatment, and at mid-treatment at 3 mo [WMD = 11.30, 95%CI: 7.33 to 15.27, I(2) = 0%] after mid-treatment, the PRP group demonstrated better outcomes than the control group. Post-treatment patient satisfaction [WMD = 1.07, 95%CI: 0.84 to 1.35, I(2) = 0%], Achilles tendon thickness [WMD = 0.34, 95%CI: -0.04 to 0.71, I(2) = 61%] and return to sport [WMD = 1.11, 95%CI: 0.87 to 1.42, I(2) = 0%] were not significantly different between the PRP and control groups. The study did not find any statistically significant distinction between the groups that received PRP treatment and those that did not, regarding the Victorian Institute of Sport Assessment - Achilles scores at 3 mo [WMD = -1.49, 95%CI: -5.24 to 2.25, I(2) = 0%], 6 mo [WMD = -0.24, 95%CI: -3.80 to 3.32, I(2) = 0%], and 12 mo [WMD = -2.02, 95%CI: -5.34 to 1.29, I(2) = 87%] for ATR patients. Additionally, no significant difference was observed between the PRP and the control groups in improving Heel lift height respectively at 6 mo [WMD = -3.96, 95%CI: -8.61 to 0.69, I(2) = 0%] and 12 mo [WMD = -1.66, 95%CI: -11.15 to 7.83, I(2) = 0%] for ATR patients. There was no significant difference in calf circumference between the PRP group and the control group after 6 mo [WMD = 1.01, 95%CI: -0.78 to 2.80, I(2) = 54%] and 12 mo [WMD = -0.55, 95%CI: -2.2 to 1.09, I(2) = 0%] of treatment. There was no significant difference in ankle mobility between the PRP and control groups at 6 mo of treatment [WMD = -0.38, 95%CI: -2.34 to 1.58, I(2) = 82%] and after 12 mo of treatment [WMD = -0.98, 95%CI: -1.41 to -0.56, I(2) = 10%] there was a significant improvement in ankle mobility between the PRP and control groups. There was no significant difference in the rate of return to exercise after treatment [WMD = 1.20, 95%CI: 0.77 to 1.87, I(2) = 0%] and the rate of adverse events [WMD = 0.85, 95%CI: 0.50 to 1.45, I(2) = 0%] between the PRP group and the control group. CONCLUSION: The use of PRP for AT improved the patient’s immediate VAS scores but not VISA-A scores, changes in Achilles tendon thickness, patient satisfaction, or return to sport. Treatment of ATR with PRP injections alone improved long-term ankle mobility but had no significant effect on VISA-A scores, single heel lift height, calf circumference or return to sport. Additional research employing more extensive sampling sizes, more strict experimental methods, and standard methodologies may be necessary to yield more dependable and precise findings. Baishideng Publishing Group Inc 2023-06-18 /pmc/articles/PMC10292057/ /pubmed/37377997 http://dx.doi.org/10.5312/wjo.v14.i6.485 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Meta-Analysis
Huang, Dan
Vithran, Djandan Tadum Arthur
Gong, Hao-Li
Zeng, Ming
Tang, Zhong-Wen
Rao, Zhou-Zhou
Wen, Jie
Xiao, Sheng
Effectiveness of platelet-rich plasma in the treatment of Achilles tendon disease
title Effectiveness of platelet-rich plasma in the treatment of Achilles tendon disease
title_full Effectiveness of platelet-rich plasma in the treatment of Achilles tendon disease
title_fullStr Effectiveness of platelet-rich plasma in the treatment of Achilles tendon disease
title_full_unstemmed Effectiveness of platelet-rich plasma in the treatment of Achilles tendon disease
title_short Effectiveness of platelet-rich plasma in the treatment of Achilles tendon disease
title_sort effectiveness of platelet-rich plasma in the treatment of achilles tendon disease
topic Meta-Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292057/
https://www.ncbi.nlm.nih.gov/pubmed/37377997
http://dx.doi.org/10.5312/wjo.v14.i6.485
work_keys_str_mv AT huangdan effectivenessofplateletrichplasmainthetreatmentofachillestendondisease
AT vithrandjandantadumarthur effectivenessofplateletrichplasmainthetreatmentofachillestendondisease
AT gonghaoli effectivenessofplateletrichplasmainthetreatmentofachillestendondisease
AT zengming effectivenessofplateletrichplasmainthetreatmentofachillestendondisease
AT tangzhongwen effectivenessofplateletrichplasmainthetreatmentofachillestendondisease
AT raozhouzhou effectivenessofplateletrichplasmainthetreatmentofachillestendondisease
AT wenjie effectivenessofplateletrichplasmainthetreatmentofachillestendondisease
AT xiaosheng effectivenessofplateletrichplasmainthetreatmentofachillestendondisease